
|Articles|January 15, 2003
Iris color changes less in eyes treated with unoprostone
Orlando-The incidence of iris hyperpigmentation associated with unoprostone isopropyl ophthalmic solution 0.15% (Rescula, Novartis) was about 1% in two long-term studies, a rate that compares favorably with the incidence of 10% to 20% associated with latanoprost ophthalmic solution (Xalatan, Pharma-cia) in similar patient populations, reported Bernard E. McCarey, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
2
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
3
Collarettes common but largely stable in moderate-to-severe dry eye patients
4
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada
5

















































.png)


